Àwọn ìtọ́jú bíi mélòó kan wà fún àrùn jẹjẹrẹ kòkòrò náà, ó sinmi lórí bí àrùn náà ṣe le tó àti bí àrùn náà ṣe le tó, àti bí ìlera aláìsàn náà ṣe rí àti ohun tó fẹ́.
Àwọn ìtọ́jú kan tí wọ́n sábà máa ń lò ni:
1. Àkíyèsí tó ń gbéṣẹ́: Ọ̀nà yìí ni pé kí wọ́n máa ṣọ́ àrùn jẹjẹrẹ náà dáadáa, kí wọ́n máa ṣe àyẹ̀wò àti àyẹ̀wò déédéé, dípò kí wọ́n tètè bẹ̀rẹ̀ ìtọ́jú.
Ó lè wúlò fún àwọn ọkùnrin tí àrùn jẹjẹrẹ kòkòrò kòkòrò kòkòrò kòkòrò wà.
2. Ìṣẹ́ abẹ: Ìṣẹ́ abẹ tí wọ́n ń pè ní prostatectomy ni iṣẹ́ abẹ tí wọ́n fi ń yọ ẹ̀jẹ̀ kòkòrò náà kúrò.
A lè ṣe é nípasẹ̀ iṣẹ́ abẹ tó ṣí sílẹ̀ tàbí nípasẹ̀ laparoscopic (tí a fi àwọn àlàfo kéékèèké àti àwọn ohun èlò àkànṣe ṣe é).
3. Ìtọ́jú nípa ìmọ́lẹ̀: Ìtọ́jú yìí máa ń lo ìmọ́lẹ̀ tó lágbára gan-an láti pa àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ.
Wọ́n lè gbé e jáde níta (láti inú ẹ̀rọ kan tó wà níta ara) tàbí láti inú ara (nípasẹ̀ àwọn ohun èlò tí wọ́n fi sínú ara tí wọ́n fi sítòsí àrùn jẹjẹrẹ).
4. Ìtọjú hormone: Ìtọjú yìí máa ń dín iye àwọn èròjà hormone ọkùnrin (androgens) tó wà nínú ara kù, èyí tó lè mú kí àrùn jẹjẹrẹ kòkòrò kòkòrò náà dín kù tàbí kó dá a dúró.
O le ṣee lo nikan tabi ni apapo pẹlu awọn itọju miiran.
5. Ìtọ́jú oògùn olóró: Ìtọ́jú yìí máa ń lo oògùn láti pa àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ.
Wọ́n lè lò ó fún àrùn jẹjẹrẹ kòkòrò kòkòrò tó ti tàn kálẹ̀ sí àwọn apá mìíràn nínú ara.
6. Ìtọjú àjẹsára: Ìtọjú yìí máa ń ran ètò àjẹsára lọ́wọ́ láti gbógun ti àrùn jẹjẹrẹ.
Wọ́n lè lò ó fún àrùn jẹjẹrẹ kòkòrò kòkòrò tí kò tíì fèsì sí ìtọ́jú mìíràn.
7. Ìlànà ìtọ́jú tí wọ́n gbé kalẹ̀: Ìlànà ìtọ́jú yìí dá lórí àwọn àbùdá tàbí èròjà protein kan pàtó tó ń ran àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ lọ́wọ́ láti dàgbà kí wọ́n sì wà láàyè.
Wọ́n lè lò ó fún àrùn jẹjẹrẹ kòkòrò kòkòrò tí kò tíì fèsì sí ìtọ́jú mìíràn.
8. Ìtọ́jú tí wọ́n ń pè ní cryotherapy: Ìtọ́jú yìí máa ń lo òtútù gan-an láti fi pa àwọn sẹ́ẹ̀lì àrùn jẹjẹrẹ run.
Wọ́n lè lò ó fún àrùn jẹjẹrẹ kòkòrò kòkòrò kòkòrò tó ti bẹ̀rẹ̀ tàbí fún àrùn jẹjẹrẹ tó ti padà wá lẹ́yìn tí wọ́n ti ṣe àwọn ìtọ́jú mìíràn.
9. High-intensity focused ultrasound (HIFU): Ìtọjú yìí máa ń lo àwọn ìgbì ohùn tó máa ń gbóná gan-an láti fi gbóná pa àwọn sẹ́ẹ̀lì jẹjẹrẹ run.
Wọ́n lè lò ó fún àrùn jẹjẹrẹ kòkòrò kòkòrò kòkòrò tó ti bẹ̀rẹ̀ tàbí fún àrùn jẹjẹrẹ tó ti padà wá lẹ́yìn tí wọ́n ti ṣe àwọn ìtọ́jú mìíràn.
10. Ìfọkànbalẹ̀: Ọ̀nà yìí ni pé kí wọ́n máa ṣọ́ àrùn jẹjẹrẹ náà dáadáa, kí wọ́n máa ṣe àyẹ̀wò àti àyẹ̀wò déédéé, àmọ́ kí wọ́n má ṣe bẹ̀rẹ̀ ìtọ́jú àyàfi tí àwọn àmì náà bá fara hàn tàbí tí wọ́n bá yí padà.
Ó lè wúlò fún àwọn ọkùnrin àgbàlagbà tó ní àrùn jẹjẹrẹ kòkòrò kòkòrò àti àwọn àìsàn míì tó le gan-an.
Ó ṣe pàtàkì láti jíròrò gbogbo ọ̀nà ìtọ́jú pẹ̀lú ẹgbẹ́ olùtọ́jú ìlera láti pinnu ọ̀nà tó dára jùlọ láti gbà ṣe nǹkan fún ọ̀kọ̀ọ̀kan àwọn ọ̀ràn náà.
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021, 178 (2): 239-261.
Talkar SS, Patravale VB: Gene Therapy for Prostate Cancer: A Review. Endocr Metab Immune Disord Drug Targets. 2021, 21 (3): 385-396.
Šamija I, Fröbe A: CHALLENGES IN MANIPULATING IMMUNE SYSTEM TO TREAT PROSTATE CANCER. Acta Clin Croat. 2019, 58 (Suppl 2): 76-81.
Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M: The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol. 2006, 176 (6 Pt 2): S47-9.
Abraham-Miranda J, Awasthi S, Yamoah K: Immunologic disparities in prostate cancer between American men of African and European descent. Crit Rev Oncol Hematol. 2021, 164 (): 103426.
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, Bangma CH, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Dautzenberg IJ, de Ridder C, Dzojic H, Erbacher P, Essand M, Fisher K, Frazier A, Georgopoulos LJ, Jennings I, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Magnusson M, Maitland N, Neuberg P, Nugent R, Ogris M, Remy JS, Scaife M, Schenk-Braat E, Schooten E, Seymour L, Slade M, Szyjanowicz P, Totterman T, Uil TG, Ulbrich K, van der Weel L, van Weerden W, Wagner E, Zuber G: Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010, 21 (7): 795-805.
Lee E, Ha S, Logan SK: Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. PLoS One. 2015, 10 (10): e0141589.
Ìyàsímímọ́: ìtọ́jú ìlera
Oju opo wẹẹbu yii ni a pese fun eto-ẹkọ ati awọn idi alaye nikan ati pe ko ṣe agbekalẹ pese imọran iṣoogun tabi awọn iṣẹ ọjọgbọn.
A ò gbọ́dọ̀ lo ìsọfúnni tó wà nínú ìwé náà láti ṣe àyẹ̀wò tàbí láti wo àìsàn tàbí àìsàn kan wò, àwọn tó bá sì ń wá ìmọ̀ràn nípa ìṣègùn fúnra wọn gbọ́dọ̀ bá dókítà tó ní ìwé àṣẹ sọ̀rọ̀.
Jọwọ ṣe akiyesi nẹtiwọọki neural ti o ṣe agbejade awọn idahun si awọn ibeere, jẹ pataki ti ko tọ nigbati o ba de si akoonu nọmba. Fun apẹẹrẹ, nọmba awọn eniyan ti a ṣe ayẹwo pẹlu aisan kan pato.
Nigbagbogbo wa imọran ti dokita rẹ tabi olupese ilera ti o ni oye miiran nipa ipo iṣoogun kan. Maṣe gbagbe imọran iṣoogun ọjọgbọn tabi idaduro ni wiwa rẹ nitori nkan ti o ti ka lori oju opo wẹẹbu yii. Ti o ba ro pe o le ni pajawiri iṣoogun, pe 911 tabi lọ si yara pajawiri ti o sunmọ julọ lẹsẹkẹsẹ. Ko si ibatan dokita-aisan ti a ṣẹda nipasẹ oju opo wẹẹbu yii tabi lilo rẹ. Bẹni BioMedLib tabi awọn oṣiṣẹ rẹ, tabi ẹnikẹni ti o ṣe alabapin si oju opo wẹẹbu yii, ṣe eyikeyi awọn aṣoju, ṣalaye tabi tumọ, pẹlu ọwọ si alaye ti a pese nibi tabi lilo rẹ.
Ìyàsímímọ́: ẹ̀tọ́ ọmọnìyàn
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) n pese atunṣe fun awọn onihun aṣẹ-aṣẹ ti o gbagbọ pe ohun elo ti o han lori Intanẹẹti ṣe ilokulo awọn ẹtọ wọn labẹ ofin aṣẹ-aṣẹ AMẸRIKA.
Ti o ba gbagbọ ni igbagbọ to dara pe eyikeyi akoonu tabi ohun elo ti o wa ni asopọ pẹlu oju opo wẹẹbu wa tabi awọn iṣẹ ṣe ilokulo aṣẹ-aṣẹ rẹ, iwọ (tabi aṣoju rẹ) le firanṣẹ akiyesi kan si wa ti o beere pe a yọ akoonu tabi ohun elo naa kuro, tabi idilọwọ iraye si rẹ.
A gbọdọ firanṣẹ awọn iwifunni ni kikọ nipasẹ imeeli (wo abala "Ibaṣepọ" fun adirẹsi imeeli).
DMCA nilo pe akiyesi rẹ ti ilokulo aṣẹ-aṣẹ ti a fi ẹsun kan pẹlu alaye wọnyi: (1) apejuwe ti iṣẹ ti o ni aṣẹ-aṣẹ ti o jẹ koko-ọrọ ti ilokulo ti a fi ẹsun kan; (2) apejuwe ti akoonu ti a fi ẹsun kan ati alaye ti o to lati gba wa laaye lati wa akoonu naa; (3) alaye olubasọrọ fun ọ, pẹlu adirẹsi rẹ, nọmba foonu ati adirẹsi imeeli; (4) alaye nipasẹ rẹ pe o ni igbagbọ rere pe akoonu ni ọna ti o ni ẹsun ti ko ni aṣẹ nipasẹ eni aṣẹ-aṣẹ, tabi aṣoju rẹ, tabi nipasẹ iṣẹ ti ofin eyikeyi;
(5) ìpolongo kan láti ọ̀dọ̀ rẹ, tí o fìdí rẹ̀ múlẹ̀ lábẹ́ ìjìyà ẹ̀rí èké, pé ìsọfúnni tó wà nínú ìkéde náà tọ̀nà àti pé o ní àṣẹ láti mú kí àwọn ẹ̀tọ́ ọmọnìyàn tí wọ́n sọ pé wọ́n ti rú ṣẹ ṣẹ;
ati (6) ibuwọlu ti ara tabi itanna ti ẹni ti o ni aṣẹ tabi eniyan ti o ni aṣẹ lati ṣiṣẹ ni orukọ ẹni ti o ni aṣẹ.
Ti o ko ba ṣafikun gbogbo alaye ti o wa loke le ja si idaduro ti ṣiṣe ẹdun rẹ.
Ìfọ̀rọ̀wérọ̀
Jọwọ fi imeeli ranṣẹ si wa pẹlu eyikeyi ibeere / imọran.
How to treat prostate cancer?
There are several treatment options available for prostate cancer, depending on the stage and aggressiveness of the cancer, as well as the patient's overall health and personal preferences.
Some common treatments include:
1. Active surveillance: This approach involves closely monitoring the cancer with regular checkups and tests, rather than immediately starting treatment.
It may be suitable for men with low-risk prostate cancer.
2. Surgery: A prostatectomy is a surgical procedure to remove the prostate gland.
It can be done through open surgery or laparoscopically (using small incisions and specialized tools).
3. Radiation therapy: This treatment uses high-energy radiation to kill cancer cells.
It can be delivered externally (from a machine outside the body) or internally (through implants placed near the tumor).
4. Hormone therapy: This treatment reduces the levels of male hormones (androgens) in the body, which can slow or stop the growth of prostate cancer.
It can be used alone or in combination with other treatments.
5. Chemotherapy: This treatment uses drugs to kill cancer cells.
It may be used for advanced prostate cancer that has spread to other parts of the body.
6. Immunotherapy: This treatment helps the immune system fight cancer.
It may be used for advanced prostate cancer that has not responded to other treatments.
7. Targeted therapy: This treatment targets specific genes or proteins that help cancer cells grow and survive.
It may be used for advanced prostate cancer that has not responded to other treatments.
8. Cryotherapy: This treatment uses extreme cold to freeze and kill cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
9. High-intensity focused ultrasound (HIFU): This treatment uses high-frequency sound waves to heat and destroy cancer cells.
It may be used for early-stage prostate cancer or for cancer that has come back after other treatments.
10. Watchful waiting: This approach involves closely monitoring the cancer with regular checkups and tests, but not starting treatment unless symptoms appear or change.
It may be suitable for older men with slow-growing prostate cancer and other serious health conditions.
It is important to discuss all treatment options with a healthcare team to determine the best course of action for each individual case.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Ní nǹkan bí
BioMedLib nlo awọn kọnputa adaṣe (awọn alugoridimu ẹkọ ẹrọ) lati ṣe agbejade awọn tọkọtaya ibeere ati idahun.
A bẹrẹ pẹlu awọn atẹjade biomedical miliọnu 35 ti PubMed/Medline. Pẹlupẹlu, awọn oju-iwe wẹẹbu ti RefinedWeb.
